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Abstract
Introduction: Centromere protein A (CENP-A), an essential centromere protein, has been associated with high
grade cancers. This study was undertaken to determine if CENP-A is a prognostic factor for breast cancer patients
not receiving systemic therapy or predictive of response to tamoxifen or neoadjuvant chemotherapy.
Methods: mRNA levels of CENP-A and CENP-B, a centromere protein that binds independently of CENP-A, were
measured in breast cancer specimens from 484 patients receiving no systemic therapy, 276 patients receiving
tamoxifen, and 233 patients treated with neoadjuvant chemotherapy. Associations between CENP-A, CENP-B, Ki-67,
relapse, and chemotherapy response were determined.
Results: CENP-A but not CENP-B was higher in estrogen receptor (ER)-negative tumors than ER-positive tumors
and positively correlated with Ki-67 expression. Among patients with ER-positive disease who received no systemic
therapy or tamoxifen, higher levels of CENP-A were associated with lower rates of 5-year distant relapse free
survival (DRFS). On multivariate analyses including Ki-67, high CENP-A expression had a hazard ratio of 10.9 for
relapse in patients with ER-positive disease not receiving systemic therapy (95% CI, 2.86 to 41.78; P = 0.00047) and
1.64 for patients with ER-positive disease receiving tamoxifen (95% CI, 0.99 to 2.71; P = 0.054). CENP-A was not an
independent prognostic marker in ER-negative tumors. For both ER-positive and ER-negative tumors, CENP-A was
not a significant independent predictor of chemotherapy response.
Conclusions: CENP-A was a significant independent prognostic marker for patients with ER-positive breast cancer
not treated with systemic therapy but had limited predictive value in tamoxifen treated patients and was not
predictive of response to neoadjuvant chemotherapy.
Introduction
Faithful chromosome segregation during cell division
requires precise assembly of the kinetochore protein
complex on centromeric chromatin [1]; aberrations in
this process cause chromosomal instability and aneu-
ploidy [2]. Because the DNA sequence of centromeres is
not conserved, it is widely thought that the marker of
centromere location is a protein, centromere protein-A
(CENP-A). It is a 17 kDa variant of histone H3 and is
found at all active centromeres [2,3]. Overexpression of
CENP-A causes ectopic formation of multicentric chro-
mosomes and functional kinetochores [4]. Inversely,
depletion of CENP-A promotes apoptosis and induces
cell cycle arrest [5,6].
Extending these observations, recent translational
work has shown that CENP-A is elevated in tumor cells
compared to normal [6,7]. Increased expression of
CENP-A is associated with higher grade cancers [6,8]
and increased invasiveness [8]. Consequently, CENP-A
has been included in predictive genetic profiles in breast
cancer [9,10]. These observations suggest that elevated
CENP-A may be correlated with poorer patient
outcomes.
Recent results also suggest that CENP-A is recruited
to sites of DNA damage and may participate in repair of
double strand DNA breaks [11]. Because of this possible
role in DNA repair, elevated levels of CENP-A might
promote resistance to chemotherapy.
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CENP-A may also provide unique prognostic and pre-
dictive information in estrogen receptor (ER)-positive
breast cancer. At least two different mechanisms for the
influence of the ER on CENP-A are possible. In the first,
the transcription factor, forkhead box protein M1
(FOXM1) is essential for transcription of CENP-A [12].
Recent work has shown that ER alpha regulates FOXM1
expression in breast cancer cell lines [13], suggesting a
pathway for ER to modulate CENP-A levels. In a second
possible mechanism, estrogen exposure increases expres-
sion of Aurora A kinase [14], which is required to phos-
phorylate CENP-A for proper kinetochore function at
mitosis [15]. In ER-positive disease, there may be higher
levels of phosphorylated CENP-A and more functional
kinetochore complexes compared to ER-negative disease.
Moreover, both of these potential mechanisms of estro-
gen-driven CENP-A modulation may result in greater
sensitivity to tamoxifen in cells overexpressing CENP-A.
To further explore these hypotheses, we analyzed
CENP-A as a prognostic and predictive biomarker in
ER-positive and ER-negative breast cancer. The associa-
tion of CENP-A with outcome was determined in two
distinct groups of patients: 484 patients from two data-
sets of patients receiving no systemic therapy and 276
patients receiving tamoxifen alone. To determine if
CENP-A predicted for response to chemotherapy, the
association of CENP-A with the volume of residual dis-
ease was determined in 233 patients treated with neoad-
juvant chemotherapy.
As a control, we compared CENP-A with centromere
protein-B (CENP-B), a protein that localizes to the cen-
tromere independently of CENP-A [16] and remains at
the centromere throughout the cell cycle [3]. Previous
work has shown that in normal cells, almost all of the
CENP-A co-localizes with CENP-B. In tumor cells over-
expressing CENP-A, more than ten percent of CENP-A
no longer co-localizes with CENP-B [7], suggesting that
excess CENP-A binds at non-centromeric regions.
ER status has emerged as a determinant of genetic pro-
files of breast cancer [17]. The results described below
explore the role of CENP-A as a prognostic and predic-
tive marker in ER-positive and ER-negative breast cancer.
Materials and methods
Patient populations
To determine the prognostic ability of CENP-A, we used
two separate datasets of clinically node-negative patients
who did not receive systemic therapy. The first is a
cohort of 289 patients previously described by Wang, et
al. [18] with gene expression data publicly available at
the Gene Expression Omnibus (GEO) database [GEO:
GSE2034]. The second is a series of 198 patients pre-
viously reported by the TRANSBIG consortium [19]
with gene expression data available at the GEO database
[GEO:GSE7390]. To evaluate the ability of CENP-A to
predict response to tamoxifen, we used a dataset of 276
patients from the Institut Jules Bordet (JBI) [10,20,21].
Expression data are available at the GEO database
[GEO:GSE2990]. Finally, to determine the value of
CENP-A as a predictor of response to neoadjuvant che-
motherapy, the MDA233 dataset of 233 patients treated
with either weekly (80 mg/m2 for 12 doses) or once
every three weeks (225 mg/m2 for four doses) paclitaxel
followed by four cycles of 5-fluorouracil (500 mg/m2),
doxorubicin (50 mg/m2), and cyclophosphamide (500
mg/m2; T/FAC) was used. Response to chemotherapy
was categorized using the residual cancer burden (RCB)
index based on residual disease at the time of surgery.
Patients were categorized as having no (RCB = 0), mini-
mal (RCB = 1), moderate (RCB = 2) or extensive (RCB
= 3) residual disease as previously described [22]. Gene
expression data from this cohort have been previously
described [23,24] and are available at the MD Anderson
Bioinformatics website [25]. For all four datasets, ER sta-
tus was determined using ligand binding assay [18,21],
EIA [18], or immunohistochemistry [18,19,24]. A sum-
mary of dataset properties is shown in Figure 1. Patient
characteristics for all four datasets are shown in Table 1.
Gene expression analysis
For all four datasets, mRNA expression levels were mea-
sured using the Affymetrix HG-U133A Gene Chip
(Santa Clara, CA, USA) using standard procedures as
previously described [18,19,21,24]. mRNA levels were
normalized using the MAS5 method to a target intensity
of 600 followed by log2-transformation [26]. After nor-
malization and transformation, a one-point increase in
log2-transformed value corresponds to a doubling of
mRNA expression. The following Affymetrix U133A
probe set identification codes were used: CENP-A,
204962_s_at; CENP-B, 212437_at; HER2, 216836_s_at;
Ki-67, 212022_s_at; and ESR1, 205225_at.
Statistical analysis
Correlations between CENP-A, CENP-B levels and ER
status; CENP-A and RCB; and CENP-A and grade were
assessed by analysis of variance (ANOVA) tests.
To analyze patient outcomes, Kaplan-Meier survival
curves [27] for distant relapse-free survival (DRFS) were
generated using tertile levels of expression of CENP-A, as
there are no published levels of CENP-A expression to
use as cutoffs. All cutoff levels were determined prior to
data analysis. Survival curves were compared using the
log-rank test. For all comparisons, statistical significance
was set at P < 0.05, and all P-values were two-sided.
Univariate and multivariate Cox regression analyses
were performed to identify correlations between vari-
ables and DRFS up to 5 years for the Wang, TRANSBIG
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and JBI datasets. Age, estrogen receptor alpha (ESR1)
gene expression level, CENP-A gene expression level,
Ki-67 gene expression level, and Her2/neu gene expres-
sion level were treated as continuous variables. The
reference vs. comparison states for categorical variables
were, T1 vs. T2 to T4 for tumor stage, 1 to 2 vs. 3 for
tumor grade, and negative vs. positive for nodal status.
Regression analyses were not performed on the Wang
dataset due to the substantial amount of unknown data,
or for the ER-negative JBI cohort due to the low num-
ber of patients in this group.
Univariate and multivariable logistic regression ana-
lyses were performed to identify correlations between
variables and chemotherapy response (RCB, as described
above) for the MDA233 data set. Predictive variables
used were the same as in the DRFS multivariate regres-
sion analyses above.
The R statistical environment was used for all calcula-
tions [28].
Results
CENP-A and CENP-B levels
We began by determining the level of CENP-A in ER-
positive versus ER-negative tumors. In the Wang,
TRANSBIG, MDA233, and JBI datasets, the levels of
CENP-A were significantly higher in ER-negative com-
pared to ER-positive tumors (Figure 2).
We then compared the level of CENP-B in ER-positive
versus ER-negative tumors. In all datasets, CENP-B was
not different between ER-positive and ER-negative
tumors (Figure 2). CENP-B did not correlate with
CENP-A when analyzed over all patients and in the sub-
sets of ER-positive and ER-negative patients (data not
shown).
Because CENP-A is necessary for centromere specifi-
cation, higher levels of CENP-A may simply reflect
higher levels of cell division. Therefore, we determined
the correlation coefficient between CENP-A and Ki-67
in ER-positive and ER-negative tumors (Table 2). In all
four datasets of patients with ER-positive and ER-nega-
tive disease, CENP-A was positively and significantly
correlated with Ki-67. There was minimal or no correla-
tion between CENP-B and Ki-67 (Table 2).
Figure 1 Datasets used in this study.
Table 1 Patient characteristics.
Dataset Wang TRANSBIG JBI MDA233
Patients (number) 286 198 276 233
Age (y)
Median Unknown 46 64 51
Range 24 - 60 40 - 88 26 - 79
T stage
T1 0 102 107 23
T2 0 96 149 132
T3 or T4 0 0 8 78
Unknown 286 0 12 0
Tumor grade
1 0 30 50 13
2 0 83 130 96
3 0 83 47 124
Unknown 286 2 49 0
Node status
Positive 0 0 142 166
Negative 286 198 117 67
Unknown 0 0 17 0
ER status
Positive 209 134 266 142
Negative 77 64 10 91
Unknown 0 0 0 0
PR status
Positive 0 0 135 0
Negative 0 0 29 0
Unknown 286 198 112 233
Her2/neu status
Positive 0 0 0 142
Negative 0 0 0 91
Unknown 286 198 276 0
ER, estrogen receptor; PR, progesterone receptor.
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Figure 2 CENP-A and CENP-B levels in estrogen receptor-negative versus estrogen receptor-positive tumors. A, CENP-A levels in Wang
dataset, P < 10-14. B, CENP-B levels in Wang dataset, P = 0.26. C, CENP-A levels in Transbig dataset, P < 10-12. D, CENP-B levels in Transbig
dataset, P = 0.06. E, CENP-A levels in JBI dataset, P = 0.018. F, CENP-B levels in JBI dataset, P = 0.57. G, CENP-A levels in MDA233 dataset, P < 10-
12. H, CENP-B levels in MDA233 dataset, P = 0.12. CENP-A, centromere protein-A; CENP-B, centromere protein-B.
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Similarly, CENP-A may also act as a surrogate marker
of grade. In the three datasets containing grade informa-
tion, CENP-A was positively and significantly correlated
with grade for ER-positive cases (Table 3). CENP-A was
also positively correlated with grade for ER-negative
samples in the TRANSBIG and MDA233 datasets
(Table 3). There were only ten patients with ER-negative
disease in the JBI dataset, so the analysis was not per-
formed on this subset.
Distant relapse-free survival
The median follow-up was 7.2 years in the Wang data-
set, 10.0 years in the TRANSBIG dataset, and 6.5 years
in the JBI dataset. Among ER-positive patients, CENP-A
levels were significantly higher in patients with a distant
relapse within five years in the untreated Wang and
TRANSBIG cohorts and in the tamoxifen-treated JBI
cohort (Figure 3). For ER-negative patients in the Wang
and TRANSBIG datasets, there was no difference in
CENP-A level between patients with and without a dis-
tant relapse at five years (data not shown).
There are no previously established cutoffs for high or
low CENP-A levels, and the distribution of CENP-A
levels did not show a clear cutoff in any of the datasets
(data not shown). Therefore, patients were grouped by
tertile of CENP-A expression. Among patients with ER-
positive disease in the untreated Wang and TRANSBIG
datasets, higher levels of CENP-A were consistently cor-
related with decreased DRFS (Figure 4). In the Wang
dataset, patients with the highest tertile of CENP-A
expression had 5-year DRFS rates of 51% compared to
68% and 83% for patients in the middle and lowest ter-
tiles of CENP-A expression (P = 0.0005, Figure 4A). A
similar pattern was found for the TRANSBIG dataset
(Figure 4B), with 5-year DRFS rates of 68%, 91%, and
100% (P = 0.0001). Among patients with ER-positive
disease who were treated with tamoxifen in the JBI data-
set, patients in the highest tertile of CENP-A expression
had 5-year DRFS of 68% vs. 86% and 90% for patients in
the middle and lowest tertile (P < 0.0008, Figure 4C).
For patients with ER-negative disease in the untreated
datasets, there was no difference in 5-year DRFS based
on tertile of CENP-A expression. In the Wang dataset,
the 5-year DRFS for patients in the highest, middle, and
lowest tertile of CENP-A level was 69%, 48%, and 58%
respectively (P = 0.5). In the TRANSBIG dataset, the 5-
year DRFS was 81%, 73%, and 48% for patients in the
highest, middle, and lowest tertile (P = 0.065).
To determine if CENP-A provides independent prog-
nostic or predictive information for DRFS, univariate and
multivariate analyses were performed with age, T stage,
tumor grade, and nodal status as categorical variables and
with ESR1, CENP-A, Ki-67, and Her2/neu gene expression
levels as continuous variables. Among patients with ER-
positive disease in the untreated TRANSBIG dataset, uni-
variate analysis revealed that grade, Ki-67, and CENP-A
were significantly associated with an increased risk of
relapse at 5 years (Table 4). To explore the interaction of
grade, Ki-67, and CENP-A, multivariate analyses of the
untreated TRANSBIG dataset were performed with and
without CENP-A (Table 4). When CENP-A was not
included in the multivariate analysis, Ki-67 was signifi-
cantly associated with DRFS (hazard ratio (HR) 2.83; 95%
confidence interval (CI), 1.48 to 5.42; P = 0.0017) and
grade was borderline significantly correlated with DRFS
(HR 2.65; 95% CI, 0.93 to 7.55; P = 0.069). When CENP-A
was included in the multivariate analysis, neither Ki-67
nor grade correlated with DRFS (Table 4).
Unexpectedly, ESR1 had a HR of 2.00 (95% CI, 1.30 to
3.08; P = 0.0015) for relapse on multivariate analysis of
ER-positive tumors in the TRANSBIG dataset (Table 4).
On univariate analysis, ESR1 was not associated with an
increased risk of relapse (HR = 1.32; 95% CI, 0.87 to
Table 2 Correlation of CENP-A and CENP-B with Ki-67 in patients with estrogen receptor-positive and estrogen
receptor-negative tumors.
ER-positive ER-negative










Wang 0.718 < 10-10 0.158 0.022 0.663 < 10-10 0.073 0.525
TRANS 0.576 < 10-13 -0.218 0.011 0.574 < 10-6 -0.090 0.480
JBI 0.638 < 10-10 -0.076 0.219 0.675 0.032 0.216 0.550
MDA233 0.655 < 10-10 -0.070 0.404 0.640 < 10-11 -0.196 0.063
TRANS, TRANSBIG study population; CENP-A, centromere protein-A; CENP-B, centromere protein-B; ER, estrogen receptor
Table 3 Correlation of centromere protein-A with grade











TRANSBIG 0.404 0.00023 0.515 < 10-5
JBI 0.518 < 10-14 — —
MDA233 0.367 0.00003 0.315 0.03
ER, estrogen receptor
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1.98, P = 0.19; Table 4). This discrepancy results sug-
gests that the significance of ESR1 seen on multivariate
analysis of the TRANSBIG dataset was the result of a
high-dimension artifact.
For patients with ER-positive disease in the tamoxifen-
treated JBI cohort, CENP-A was significantly associated
with 5-year DRFS on univariate analysis (HR 1.97, 95%





Figure 3 CENP-A levels in patients with estrogen receptor-positive disease according to distant relapse status at 5 years. A, Wang
dataset, P < 0.00007. B, TRANSBIG dataset, P < 0.000009. C, JBI dataset, P < 0.00003. CENP-A, centromere protein-A.
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on multivariate analysis (95% CI, 0.99 to 2.71, P = 0.054;
Table 5). For patients with ER-negative breast cancer in
the TRANSBIG dataset, CENP-A was not significantly
associated with DRFS on univariate (HR 0.79; 95% CI,
0.51 to 1.23; P = 0.30) or multivariate analysis (Table 6).
Similarly, for patients with ER-negative disease in the
MDA233 dataset, CENP-A was not significant for dis-
tant relapse on univariate (HR 1.38; 95% CI, 0.88 to
2.17; P = 0.16) or multivariate analysis (Table 6).
Response to neoadjuvant chemotherapy
To determine if CENP-A was associated with response
to neoadjuvant chemotherapy, the MDA233 dataset was
queried to determine CENP-A levels in patients with no
or minimal residual disease after chemotherapy (RCB =
0/1) and in patients with moderate or extensive residual
disease after chemotherapy (RCB = 2/3). In patients
with ER-positive and ER-negative disease, CENP-A
levels were higher in patients with no or minimal resi-
dual disease (Figure 5). CENP-B levels were not different
between patients in the RCB 0/1 or RCB 2/3 groups for
either ER-positive or ER-negative patients (data not
shown).
Regression analyses were performed to determine if
CENP-A level independently correlated with response to
chemotherapy. On multivariate analysis of patients with
ER-positive disease in MDA233, nodal status was mar-
ginally associated (P = 0.05) with RCB 0/1 vs. RCB 2/3
(Table 5). Similar analysis of patients with ER-negative
disease in MDA233 identified age and T stage as signifi-
cantly associated with chemotherapy response (Table 6).
Discussion
We discovered that CENP-A is an independent prognos-
tic marker for relapse in node-negative, ER-positive
breast cancers not treated with systemic therapy. On
multivariate analysis, ER-positive patients with elevated
CENP-A have a 10.9-fold increased risk of distant
relapse within five years in the absence of chemotherapy
or hormonal therapy. Furthermore, survival analysis of
two independent datasets showed that the level of
CENP-A is directly proportional to the risk of distant
relapse within five years.
CENP-A correlated with Ki-67 and grade, which have
been associated with an increased risk of relapse [29,30].
Our finding that elevated CENP-A was associated with
an increased risk of relapse even with the inclusion of
Ki-67 and grade in the regression analysis suggests that
CENP-A may have a role in recurrence that is indepen-
dent of its role as a marker of proliferation. Heun, et al.
have shown that overexpression of CENP-A causes ecto-
pic formation of functional kinetochores and multi-













Figure 4 Distant relapse-free survival in patients with estrogen
receptor-positive disease grouped by tertile of CENP-A
expression. In all panels, black line = lowest tertile of CENP-A
expression, red line = middle tertile of CENP-A expression, and
green line = highest tertile of CENP-A expression. A, Wang dataset,
P = 0.0005. B, TRANSBIG dataset, P = 0.0001. C, JBI dataset, P <
0.0008. CENP-A, centromere protein-A.
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analyzed 11 samples of colorectal cancers and found
that CENP-A was overexpressed in all of the samples. In
addition to localizing to the centromere, the overex-
pressed CENP-A also localized to non-centromeric
regions of the chromatin [7]. Together, these observa-
tions suggest a mechanism for the contribution of
CENP-A to aneuploidy and subsequent cancer
progression.
Although CENP-A correlates with Ki-67, overexpres-
sion of CENP-A independent of the higher proliferation
rates of tumor cells is further supported by the observa-
tions of Tomonga and colleagues that the level of prolif-
erating cell nuclear antigen (PCNA) was generally
similar in tumor and normal cells [7]. Additionally,
CENP-B was not correlated with CENP-A in the tumors
of patients in our current study, suggesting that elevated
levels of CENP-A are not due to increased expression of
all centromere proteins. Our observation agrees with a
previous observation that CENP-B levels are similar in
normal and colorectal tumor samples [7].
Even though CENP-A was elevated in both ER-posi-
tive and ER-negative tumors with a complete or near-
complete response to neoadjuvant chemotherapy,
CENP-A did not independently predict response to che-
motherapy. One possible reason is that because CENP-
A is proportional to Ki-67, which has predictive value
for chemotherapy response [31], CENP-A did not pro-
vide additional predictive power for chemotherapy
response. However, given the relatively modest sample
size, a small effect cannot be ruled out.
We found that ER-negative tumors had higher levels
of CENP-A than ER-positive tumors. This result is con-
sistent with several previous studies that have shown
that ER-negative breast cancer has a distinct genetic sig-
nature from ER-positive disease [32-34]. Higher levels of
CENP-A in ER-negative tumors may reflect a higher
rate of proliferation or chromosomal instability [35,36]
compared to ER-positive cancers.
Consistent with our results, Hu, et al. recently found
that Holliday Junction Recognition Protein (HJURP),
which has been proposed to act as a CENP-A-specific
chaperone responsible for the deposition of CENP-A at
centromeres [37,38], is also an independent prognostic
marker in breast cancer [39]. They showed that HJURP
levels were higher in ER-negative tumors and were
Table 4 Univariate and multivariate analyses for distant relapse at 5 years in patients with estrogen receptor-positive
disease in the TRANSBIG dataset.
Univariate analyses Multivariate analysis without CENP-A Multivariate analysis with CENP-A
Variable HR 95% CI P-value HR 95% CI P -value HR 95% CI P -value
Age 0.98 0.92-1.05 0.62 1.00 0.93-1.08 0.95 1.01 0.93-1.09 0.89
T stage 1.22 0.47-3.16 0.68 0.82 0.31-2.19 0.70 0.59 0.21-1.67 0.32
Grade 2.70 1.04-7.00 0.04 2.65 0.93-7.55 0.069 1.01 0.33-3.11 0.98
ESR1 1.32 0.87-1.98 0.19 1.63 1.05-2.52 0.025 2.00 1.30-3.08 0.0015
CENP-A 3.30 1.84-5.89 0.000056 — — — 10.93 2.86-41.78 0.00047
Ki-67 2.18 1.32-3.60 0.0022 2.83 1.48-5.42 0.0017 1.03 0.58-1.84 0.91
Her2/neu 1.11 0.74-1.66 0.63 1.14 0.79-1.65 0.49 1.10 0.77-1.58 0.60
ESR1 (estrogen receptor alpha), CENP-A (centromere protein-A), Ki-67, and Her2/neu are continuous variables reflecting mRNA levels; HR, hazard ratio; CI,
confidence interval; DRFS, distant-relapse free survival; RCB, residual cancer burden
Table 5 Multivariate analyses for distant relapse in
patients with estrogen receptor-positive disease in the
JBI and MDA233 datasets.
JBI (5 y DRFS) MDA233 (RCB 0/1)
Variable HR 95% CI P-value HR 95% CI P -value
Age 0.99 0.95-1.03 0.48 1.02 0.98-1.06 0.38
T stage 2.09 0.89-4.89 0.09 3.22 0.35-30.01 0.30
Nodal status 0.99 0.47-2.08 0.98 0.39 0.15-1.00 0.05
Grade 0.79 0.31-2.00 0.61 1.09 0.41-2.89 0.86
ESR1 1.00 0.72-1.41 0.98 0.79 0.55-1.12 0.18
CENP-A 1.64 0.99-2.71 0.054 1.30 0.75-2.28 0.35
Ki-67 1.13 0.73-1.77 0.58 1.08 0.64-1.81 0.78
Her2/neu 0.94 0.67-1.31 0.71 1.05 0.67-1.64 0.84
ESR1 (estrogen receptor alpha), CENP-A (centromere protein-A), Ki-67, and
Her2/neu are continuous variables reflecting mRNA levels; HR, Hazard ratio; CI,
confidence interval; DRFS, distant-relapse free survival; RCB, residual cancer
burden
Table 6 Multivariate analyses for distant relapse for
patients with estrogen receptor-negative disease.
TRANSBIG (5 y DRFS) MDA233 (RCB 0/1)
Variable HR 95% CI P-value HR 95% CI P -value
Age 0.99 0.92-1.07 0.84 0.93 0.88-0.98 0.01
T stage 0.81 0.29-2.26 0.69 0.06 0.00-0.82 0.035
Nodal status — — — 0.88 0.25-3.10 0.84
Grade 2.18 0.41-11.67 0.36 2.16 0.52-9.00 0.29
ESR1 0.73 0.48-1.10 0.13 0.82 0.58-1.15 0.26
CENP-A 0.49 0.20-1.20 0.12 1.32 0.65-2.66 0.44
Ki-67 0.63 0.24-1.67 0.36 1.01 0.53-1.93 0.97
Her2/neu 0.90 0.69-1.19 0.46 0.97 0.61-1.54 0.91
ESR1 (estrogen receptor alpha), CENP-A (centromere protein-A), Ki-67, and
Her2/neu are continuous variables reflecting mRNA levels; HR, Hazard ratio; CI,
confidence interval; DRFS, distant-relapse free survival; RCB, residual cancer
burden
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strongly correlated with Ki-67 and CENP-A levels.
Higher levels of HJURP were associated with decreased
survival, and on multivariate analysis for disease-free
survival, HJRUP had a HR of 2.05 [39]. Notably, this
multivariate analysis did not include Ki-67 or CENP-A,
which may have accounted for some of the variation in
survival. Clearly, future studies on the interactions of
HJRUP and CENP-A in breast cancer are warranted.
Although CENP-A levels were higher in ER-negative
tumors, CENP-A was only prognostic for DRFS in
patients with ER-positive tumors. This is consistent with
both models of estrogen modulation of CENP-A
described above. In the FOXM1 mechanism, increased
ER signaling would increase levels of FOXM1, resulting
in increased levels of CENP-A. In agreement with this,
recent work has shown that FOXM1 is an independent
prognostic marker in ER-positive but not ER-negative
breast cancer [40]. In the Aurora A kinase model, estro-
gen drives overexpression of Aurora A kinase [14],
which is required for phosphorylation of CENP-A and
subsequent kinetochore function [15]. It is possible that
the presence of elevated levels of both CENP-A and
Aurora A in ER-positive tumors would portend a worse
outcome than the presence of increased levels of CENP-
A alone. Estrogen-driven expression of Aurora A would
be absent from ER-negative tumors, which might
account for the lack of prognostic utility of CENP-A in
ER-negative tumors.
In the tamoxifen-treated JBI dataset, CENP-A was
higher in patients with a distant relapse, and the level of
CENP-A was directly proportional to the risk of relapse.
The borderline significance of CENP-A on multivariate
analysis for DRFS in the JBI dataset most likely reflects
the strong prognostic role of CENP-A in ER-positive
patients as seen in the Wang and TRANSBIG cohorts
that did not receive systemic therapy. Alternatively, it is
possible that treatment with tamoxifen blocks estrogen-
driven modulation of CENP-A via either the FOXM1 or
Aurora A pathways, minimizing the influence of estro-




Figure 5 CENP-A levels in tumors of patients with no or minimal residual disease (RCB 0/1) vs. patients with moderate or extensive
residual disease (RCB 2/3) after chemotherapy. A, Patients with estrogen receptor (ER)-positive disease, P = 0.0215. B, Patients with ER-
negative disease, P = 0.0433. CENP-A, centromere protein-A.
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of tamoxifen and other hormonal therapies on mitosis
are plainly needed.
One weakness of this study is that well-known clinical
elements such as T stage and nodal status were not
robustly identified as prognostic factors across all four
datasets. This is likely the result of the variable manner
in which samples were chosen for each dataset. For
instance, samples included in the Wang dataset were
retrospectively chosen from technically satisfactory sam-
ples available from patients with good, intermediate, and
poor outcomes [18]. Moreover, 87% of these patients
received radiation, which may have affected their survi-
val. Ideally, future biomarker studies will utilize samples
collected prospectively from patients treated in a uni-
form fashion.
Conclusions
We found CENP-A to be a strong prognostic marker for
distant relapse in ER-positive breast cancer. Even when
known clinical factors such as Ki-67 and grade are con-
sidered, CENP-A remains an independent prognostic
marker for relapse, suggesting that CENP-A may contri-
bute to disease progression independent of its role as a
marker of proliferation. Moreover, the level of CENP-A
was directly proportional to the risk of distant relapse,
demonstrating a clear relationship between the degree
of expression of this essential protein and outcome in
ER-positive breast cancer.
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